Concept Life Sciences appoints Matilda Bingham as Site Director and David Higton as Biotransformation and Metabolite Identification Expert, at its Alderley Park siteApril 24, 18
Appointments support expansion of expertise in integrated drug discovery and development
Manchester, UK, 24 April 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the Alderley Park site.
Matilda has over 15 years’ experience in the pharmaceutical industry, in both biotech and pharma environments. She joins Concept from Redx Pharma, where she held positions as Head of Research and Operations, and Executive Director of Oncology and Immunology. Matilda previously also worked for MSD Research Laboratories (part of Merck). With a PhD in Organic Chemistry, Matilda has had numerous publications, patents and posters published, and has managed programmes from hit-to-lead through to the clinic across a diverse range of target classes and disease areas.
David is a highly experienced scientist with a proven track record of delivering innovative, effective solutions. He has over 34 years of expertise in bioanalytical and biotransformation studies, including 23 years at Glaxo Group Research, now GlaxoSmithKline, where he supported pre-clinical, clinical, and discovery investigations, for both non-GLP and GLP studies. David joins Concept from Cyprotex, where he was most recently Head of Analytical Sciences. Prior to this he was Analytical Team Leader at RedX Pharma, Vice President, Operations at Xceleron Inc, and Principal Scientist at AstraZeneca, leading new scientific and technological development in regulatory bioanalysis.
Philip Payne, Chief Operating Officer, Concept Life Sciences, said: “With several years’ experience of managing multidisciplinary research projects in a pharmaceutical company environment, we are delighted to have appointed Matilda to head up our new Alderley Park site, which was established in September 2017. We are also pleased to welcome David, whose expertise will be a valuable addition to the analytical team.”
Matilda Bingham, Site Director at Alderley Park, Concept Life Sciences, said: “I am looking forward to applying my own drug discovery experience alongside the already established expertise within the team to expand integrated drug discovery services at Concept, both at the Alderley Park Site and in collaboration with the Company’s other sites. The location and site infrastructure at Alderley provide us with a great opportunity to run integrated projects for customers.”
David Higton, Principal Scientist, Concept Life Sciences, said: “I am excited to be joining the Concept team at Alderley Park, as well as working at the Dundee site to establish biotransformation activities for both cold and labelled material in discovery, pre-clinical and clinical investigations. I am looking forward to bringing my wealth of experience in this area to benefit our clients.”
This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.